Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Heal

Showing results (31-40 of 182) with videos related to

Pageof 19
Sort By:
International Journal of Obesity (2005)|March 14, 2012
A review of late-stage CNS drug candidates for the treatment of obesityD J Heal, J Gosden, S L Smith
Current Topics in Behavioral Neurosciences|May 4, 2022
New Drugs to Treat ADHD: Opportunities and Challenges in Research and DevelopmentDavid J Heal, Jane Gosden, Sharon L Smith
Journal of Psychopharmacology (Oxford, England)|July 28, 2016
The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorderKatharine Pillidge, David J Heal, S Clare Stanford
Annals of the Royal College of Surgeons of England|August 10, 2000
What do trainees think about advanced trauma life support (ATLS)?B Campbell, J Heal, S Evans, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 1, 1994
Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnoverD J Heal, C Czudek, W R Buckett
Neuropharmacology|June 24, 2014
Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaineDavid J Heal, Jane Gosden, Sharon L Smith
Neuropharmacology|February 11, 2018
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humansDavid J Heal, Jane Gosden, Sharon L Smith
British Journal of Clinical Pharmacology|December 17, 2009
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersDavid J Heal, Jane Gosden, Sharon L Smith
Pharmacology, Biochemistry, and Behavior|June 19, 1998
The anxiogenic agents, yohimbine and FG 7142, disrupt the noradrenergic response to noveltyK Mason, D J Heal, S C Stanford
British Journal of Pharmacology|December 1, 1989
Chronic lithium treatment enhances inositol polyphosphate formation in mouse brain in vivoP Whitworth, D J Heal, D A Kendall
Pageof 19

Showing results (31-40 of 182) with videos related to

Sort By:
Pageof 19
International Journal of Obesity (2005)|March 14, 2012
A review of late-stage CNS drug candidates for the treatment of obesityD J Heal, J Gosden, S L Smith
Current Topics in Behavioral Neurosciences|May 4, 2022
New Drugs to Treat ADHD: Opportunities and Challenges in Research and DevelopmentDavid J Heal, Jane Gosden, Sharon L Smith
Journal of Psychopharmacology (Oxford, England)|July 28, 2016
The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorderKatharine Pillidge, David J Heal, S Clare Stanford
Annals of the Royal College of Surgeons of England|August 10, 2000
What do trainees think about advanced trauma life support (ATLS)?B Campbell, J Heal, S Evans, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 1, 1994
Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnoverD J Heal, C Czudek, W R Buckett
Neuropharmacology|June 24, 2014
Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaineDavid J Heal, Jane Gosden, Sharon L Smith
Neuropharmacology|February 11, 2018
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humansDavid J Heal, Jane Gosden, Sharon L Smith
British Journal of Clinical Pharmacology|December 17, 2009
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersDavid J Heal, Jane Gosden, Sharon L Smith
Pharmacology, Biochemistry, and Behavior|June 19, 1998
The anxiogenic agents, yohimbine and FG 7142, disrupt the noradrenergic response to noveltyK Mason, D J Heal, S C Stanford
British Journal of Pharmacology|December 1, 1989
Chronic lithium treatment enhances inositol polyphosphate formation in mouse brain in vivoP Whitworth, D J Heal, D A Kendall
Pageof 19